The safety results from the EoE KIDS study were consistent with the known safety profile of Dupixent in adolescents and ...
Sanofi (SNY) has released an update. Sanofi’s Dupixent has received EU approval as the first treatment for children aged one to 11 with ...
Allergic reactions come in all varieties. One can even trigger a digestive disease called Eosinophilic Esophagitis, which ...
GlobalData on MSN9h
AstraZeneca and Amgen’s Tezspire succeeds in Phase III nasal polyps trialThe companies’ monoclonal antibody met co-primary endpoints in a Phase III trial in patients with chronic rhinosinusitis with ...
TSLP is released in response to allergens, viruses and other airborne particles associated with asthma, COPD, CRSwNP, ...
Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitisApproval based on phase 3 data showing ...
Researchers used pharmacovigilance data to examine the onset of gastrointestinal adverse events associated with the use of biologic therapies for psoriasis.
EMA approves Dupixent to treat eosinophilic esophagitis in children as young as one year: Paris Thursday, November 7, 2024, 14:00 Hrs [IST] The European Medicines Agency has appro ...
Currently the product is in Phase III stage of development for the treatment of Eosinophilic Esophagitis. IRL201104, is ...
Paris: Sanofi has announced that the European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic ...
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ: EPRX) (TSX: EPRX), a clinical-stage biotechnology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback